Post Marketing Surveillance Study of Biphasic Insulin Aspart 30

Novo Nordisk A/S5,346 enrolled

Overview

This study is conducted in Asia. The aim of this study is to review the safety and efficacy of biphasic insulin aspart 30 in post-marketing use.

Study Type

OBSERVATIONAL

Enrollment

5,346

Conditions

Diabetes Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2

Interventions

biphasic insulin aspart 30DRUG

The insulin dose and regimen were individualised at the physician's discretion. Insulin was administered by subcutaneous injection using an injection device

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Subjects with diabetes who did not have indications that are contraindicated in the product insert

Locations (1)

Unnamed facility

Seoul, South Korea

Outcomes

Primary Outcomes

Change in body weight

Secondary Outcomes

Change in fasting plasma glucose (FPG)

Change in HbA1c (glycosylated haemoglobin)

Occurrence of adverse events (non-serious and serious)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.